Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

Author： Sebti S.M.   Hamilton A.D.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.12, 2000-12, pp. : 2767-2782

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of Farnesyltransferase and Geranylgeranyltransferase-I for Antitumor Therapy: Substrate-Based Design, Conformational Constraint and Biological Activity

By  

Current Topics in Medicinal Chemistry, Vol. 3, Iss. 10, 2003-01 ,pp. : 1075-1093

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside

By Vincenzi Bruno   Napolitano Andrea   D'Onofrio Loretta   Frezza Anna Maria   Silletta Marianna   Venditti Olga   Santini Daniele   Tonini Giuseppe  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 12, 2011-12 ,pp. : 1685-1705

Informa Healthcare

Access to resources Recommend Favorite

Regorafenib: from bench to bedside in colorectal cancer

By Shahda Safi   Saif Muhammad Wasif  

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 3, 2013-05 ,pp. : 243-248

Informa Healthcare

Access to resources Recommend Favorite

Noninvasive Molecular Detection of Cancer - the Bench and the Bedside

By  

Current Medicinal Chemistry, Vol. 10, Iss. 8, 2003-04 ,pp. : 691-706

Bentham Science Publishers

Access to resources Recommend Favorite

Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2778-2792

Bentham Science Publishers

Access to resources Recommend Favorite